Grifols SA is a global specialty plasma therapeutics company that engages in the development, manufacturing, and distribution of a broad range of biological medicines based on plasma-derived proteins. The company is headquartered in Sant Cugat Del Valles, Barcelona and currently employs 23,833 full-time employees. The company went IPO on 2006-05-17. The firm organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
Financials in millions USD. Fiscal year is February - January.
Breakdown
TTM
12/31/2025
12/31/2024
09/30/2024
06/30/2024
03/31/2024
Revenue
7,524
7,524
7,212
--
--
--
Revenue Growth (YoY)
4%
4%
--
--
--
--
Cost of Revenue
4,664
4,665
4,417
--
--
--
Gross Profit
2,859
2,859
2,794
--
--
--
Selling, General & Admin
1,130
1,063
1,144
--
--
--
Research & Development
398
373
330
--
--
--
Operating Expenses
1,607
1,608
1,639
--
--
--
Other Non Operating Income (Expenses)
-196
-127
-212
--
--
--
Pretax Income
615
615
443
--
--
--
Income Tax Expense
115
115
231
--
--
--
Net Income
402
402
156
--
--
--
Net Income Growth
158%
158%
--
--
--
--
Shares Outstanding (Diluted)
682.86
680.51
679.66
--
--
--
Shares Change (YoY)
0%
0%
--
--
--
--
EPS (Diluted)
0.58
0.59
0.23
--
--
--
EPS Growth
154%
156%
--
--
--
--
Free Cash Flow
624
624
530
158
-56
-224
Free Cash Flow Per Share
--
--
--
--
--
--
Gross Margin
37.99%
37.99%
38.74%
--
--
--
Operating Margin
16.62%
16.62%
16.01%
--
--
--
Profit Margin
5.34%
5.34%
2.16%
--
--
--
Free Cash Flow Margin
8.29%
8.29%
7.34%
--
--
--
EBITDA
1,701
1,701
1,592
--
--
--
EBITDA Margin
22.6%
22.6%
22.07%
--
--
--
D&A For EBITDA
450
450
437
327
219
105
EBIT
1,251
1,251
1,155
--
--
--
EBIT Margin
16.62%
16.62%
16.01%
--
--
--
Effective Tax Rate
18.69%
18.69%
52.14%
--
--
--
Follow-Up Questions
What are Grifols, S.A.'s key financial statements?
According to the latest financial statement (Form-10K), Grifols, S.A. has a total asset of $19,712, Net profit of $402
What are the key financial ratios for GIFLF?
Grifols, S.A.'s Current ratio is 1.36, has a Net margin is 5.34, sales per share of $11.05.
How is Grifols, S.A.'s revenue broken down by segment or geography?
Grifols, S.A. largest revenue segment is Biopharma, at a revenue of 6,142,588,000 in the most earnings release.For geography, United States and Canada is the primary market for Grifols, S.A., at a revenue of 4,087,030,000.
Is Grifols, S.A. profitable?
yes, according to the latest financial statements, Grifols, S.A. has a net profit of $402
Does Grifols, S.A. have any liabilities?
yes, Grifols, S.A. has liability of 14,441
How many outstanding shares for Grifols, S.A.?
Grifols, S.A. has a total outstanding shares of 680.57
